Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

17:07
10/05/16
10/05
17:07
10/05/16
17:07

Alnylam down 42% after drug development halt, Medicines Co. down 3.6%

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.

TODAY'S FREE FLY STORIES

NEM

Newmont Mining

$33.58

1.31 (4.06%)

, SDRL

Seadrill

$2.95

-0.13 (-4.22%)

07:30
12/05/16
12/05
07:30
12/05/16
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

NEM

Newmont Mining

$33.58

1.31 (4.06%)

SDRL

Seadrill

$2.95

-0.13 (-4.22%)

ORCL

Oracle

$38.50

-0.2 (-0.52%)

AET

Aetna

$133.49

-1.41 (-1.05%)

FE

FirstEnergy

$30.57

-0.42 (-1.36%)

LBTYA

Liberty Global

$29.67

-0.4 (-1.33%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

IRDM

Iridium

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

ITRI

Itron

$63.10

-0.7 (-1.10%)

07:28
12/05/16
12/05
07:28
12/05/16
07:28
Recommendations
Itron analyst commentary  »

Itron price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDYN

Hyperdynamics

07:28
12/05/16
12/05
07:28
12/05/16
07:28
Hot Stocks
Hyperdynamics signs LOI with SAPETRO »

Hyperdynamics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNCE

Vince Holding

$3.90

-0.35 (-8.24%)

07:27
12/05/16
12/05
07:27
12/05/16
07:27
Upgrade
Vince Holding rating change  »

Vince Holding upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

FL

Foot Locker

$74.23

0.55 (0.75%)

07:27
12/05/16
12/05
07:27
12/05/16
07:27
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NMBL

Nimble Storage

$7.72

0.28 (3.76%)

07:25
12/05/16
12/05
07:25
12/05/16
07:25
Recommendations
Nimble Storage analyst commentary  »

Nimble Storage can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

07:25
12/05/16
12/05
07:25
12/05/16
07:25
Recommendations
Amazon.com analyst commentary  »

Amazon to continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

07:25
12/05/16
12/05
07:25
12/05/16
07:25
Conference/Events
Trillium Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

QTNA

Quantenna Communications

$16.83

-0.18 (-1.06%)

07:24
12/05/16
12/05
07:24
12/05/16
07:24
Upgrade
Quantenna Communications rating change  »

Quantenna Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

07:22
12/05/16
12/05
07:22
12/05/16
07:22
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$11.07

-0.21 (-1.86%)

07:21
12/05/16
12/05
07:21
12/05/16
07:21
Hot Stocks
Canadian Solar closes financing for solar power project in Japan »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

BA

Boeing

$152.25

-0.14 (-0.09%)

, EADSY

Airbus

$15.64

-0.26 (-1.64%)

07:19
12/05/16
12/05
07:19
12/05/16
07:19
Periodicals
Norwegian Air CEO aims to order more Boeing, Airbus aircraft, Reuters reports »

Norwegian Air Shuttle CEO…

BA

Boeing

$152.25

-0.14 (-0.09%)

EADSY

Airbus

$15.64

-0.26 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$18.40

0.6 (3.37%)

07:19
12/05/16
12/05
07:19
12/05/16
07:19
Upgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$57.05

0.88 (1.57%)

07:18
12/05/16
12/05
07:18
12/05/16
07:18
Hot Stocks
Tyson Foods creates $150M venture capital fund »

As part of its commitment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SNSS

Sunesis

$3.90

-0.06 (-1.52%)

07:18
12/05/16
12/05
07:18
12/05/16
07:18
Hot Stocks
Sunesis says SNS-062 on track to begin dosing in Phase 1B/2 trial in 1H17 »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$25.26

0.05 (0.20%)

07:18
12/05/16
12/05
07:18
12/05/16
07:18
Hot Stocks
Hilton board approves 1-for-3 reverse stock split; sees spinoff completed Jan. 3 »

Hilton Worldwide Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGLS

Tecnoglass

$11.81

-0.1 (-0.84%)

07:17
12/05/16
12/05
07:17
12/05/16
07:17
Hot Stocks
Tecnoglass to acquire Florida-based E.S. Windows in $13M transaction »

Tecnoglass announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

07:16
12/05/16
12/05
07:16
12/05/16
07:16
Recommendations
Alnylam analyst commentary  »

Alnylam's fitusiran…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVAX

Dynavax

$4.70

0.35 (8.05%)

07:15
12/05/16
12/05
07:15
12/05/16
07:15
Hot Stocks
Dynavax presents clinical data from SD-101 at ASH meeting »

Dynavax Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

07:15
12/05/16
12/05
07:15
12/05/16
07:15
Recommendations
Spark Therapeutics analyst commentary  »

Spark may be pressured…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ONTX

Onconova

$2.62

-0.23 (-8.07%)

07:14
12/05/16
12/05
07:14
12/05/16
07:14
Hot Stocks
Onconova presents Phase 2 data from rigosertib/azacitidine combination »

Onconova Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

F

Ford

$12.24

-0.19 (-1.53%)

07:14
12/05/16
12/05
07:14
12/05/16
07:14
Periodicals
Ford still moving small-car production to Mexico, WSJ reports »

Ford Motor is still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Jan

  • 10

    Jan

GLOG

GasLog

$15.95

0.45 (2.90%)

, GLOP

GasLog Partners

$20.60

-0.05 (-0.24%)

07:14
12/05/16
12/05
07:14
12/05/16
07:14
Hot Stocks
GasLog announces order of FSRU LLIs »

GasLog (GLOG) announces…

GLOG

GasLog

$15.95

0.45 (2.90%)

GLOP

GasLog Partners

$20.60

-0.05 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

VBLT

VBL Therapeutics

$5.25

0.05 (0.96%)

07:13
12/05/16
12/05
07:13
12/05/16
07:13
Hot Stocks
VBL says DSMC recommends Phase 3 GLOBE study continue as planned »

VBL Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

07:13
12/05/16
12/05
07:13
12/05/16
07:13
Hot Stocks
Sorrento Therapeutics subsidiary says key endpoints met in ZTlido study »

SCILEX Pharmaceuticals, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.